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OBJECTIVES This study was designed to determine the magnitude and time course of platelet activation
during therapy of acute coronary syndromes with an oral platelet antagonist.
BACKGROUND Platelet activation and aggregation are central to the pathogenesis of the acute coronary
syndromes (ACS). However, few data are available on levels of platelet activation over time
in patients with ACS, especially in the setting of chronic glycoprotein (GP) IIb/IIIa
inhibition.
METHODS The Thrombolysis in Myocardial Infarction (TIMI) 12 trial was a phase II, double-blind trial
evaluating the effects of sibrafiban, an oral, selective antagonist of the platelet glycoprotein
IIb/IIIa receptor in patients stabilized after an ACS. A subset of 90 of the 329 patients in the
study had measurement of platelet activation as assessed by the expression of platelet
associated P-Selectin on days 0, 7 and 28. Platelet activation was measured in blood samples
that were fixed either immediately (spontaneous activation) or after 5 minute incubation with
0, 1 mM or 5 mM ADP in order to assess platelet responsiveness to very low or moderate
stimulation.
RESULTS At baseline there was a significant elevation of spontaneous platelet activation as compared to
samples obtained from normal donors or from patients who did not have acute coronary
syndromes (ACS patients 27.6 6 18.7%, Normal controls 8.5 6 4.4%, Patient controls
10.9 6 7.1%, p , 0.005 for both). In addition, there was a significant decrease in the levels
of platelet activation with time during the 28 days of treatment with sibrafiban. Nevertheless,
even on day 28, the TIMI-12 patients continued to show elevated platelet activation in
comparison to the control groups (p , 0.05 for both).
CONCLUSIONS These results suggest that platelets remain activated long after clinical stabilization post ACS.
Although platelet activation decreased after one month of oral GPIIb/IIIa inhibition, levels
remained higher than normal, suggesting the need for long-term antiplatelet therapy
following ACS. (J Am Coll Cardiol 1999;33:634–9) © 1999 by the American College of
Cardiology
There is abundant evidence that platelet activation occurs
during acute coronary syndromes and that measurement of
platelet activation and/or aggregation, may provide prog-
nostic information in patients suffering a first or second
event (1–11). In addition, there is evidence that inhibition
of platelet function through the use of aspirin and inhibitors
of platelet glycoprotein (GP) IIb/IIIa function lowers the
risk of first and subsequent cardiac events (12–16). What
remains uncertain is to what extent the increased platelet
activation observed is due to the disease process itself, i.e.,
activation of platelets within the abnormal coronary circu-
lation, or to a genetic or environmental propensity for
platelets to become activated more easily in response to
minimal stimuli. In the former case, one would expect that
platelet status would return to normal early after the
resolution of the acute event, whereas, in the latter case
platelet function may remain abnormal for a considerable
time or indefinitely. With the advent of potentially much
more powerful platelet inhibitors such as oral GPIIb/IIIa
antagonists (17–19), the possibility of prolonged treatment
with these drugs may make it important to determine both
the extent and the duration of platelet dysfunction following
a coronary event.
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We (20–24) and others (1,7,25–27) have used platelet
associated P-Selectin as a sensitive, quantitative measure of
platelet activation. The P-Selectin molecule has the advan-
tage that its antigenic epitopes are relatively stable to
fixation and it thus lends itself to multicenter clinical
studies. The TIMI-12 trial was a study of the safety and
effectiveness of prolonged (28 day) administration of an oral
glycoprotein IIb/IIIa inhibitor (sibrafiban) in patients who
had suffered an acute coronary syndrome (18). P-Selectin
measurements were included in the pharmacokinetic/
pharmacodynamic cohort of the TIMI-12 trial in order to
determine if there were detectable changes in platelet
activation during the course of the disease process and
whether the study drug had an effect on platelet activation in
addition to its known effect on platelet aggregation.
MATERIALS AND METHODS
The monoclonal antibody 1E3, a CD62P antibody directed
against P-Selectin was derived in our laboratory as previ-
ously reported (23). It was biotinylated by standard meth-
ods. Phycoerythrin conjugated streptavidin was obtained
from Southern Biotech, Birmingham, Alabama. Fluorescein
conjugated monoclonal antibody directed against glycopro-
tein GPIIb/IIIa (CD41) was obtained from Immunotech
Inc., Westbrook, Maine. All reagents were used in saturat-
ing concentrations as determined by titration on fully
activated platelet samples.
A complete description of the clinical characteristics of
the TIMI-12 subjects and the sites participating has been
previously published (18). Briefly, the subjects had suffered
the onset of an acute coronary syndrome (unstable angina,
non-Q-wave myocardial infarction [MI] or Q-wave MI)
between 24 hours and 7 days prior to randomization.
Patients were required to be clinically stable, i.e., no
ongoing ischemia, no congestive heart failure, and not on
intravenous heparin. They were randomized to receive one
of seven different dose regimens of sibrafiban for 28 days; all
subjects received some dose of study drug in a double-blind
fashion. No other GPIIb/IIIa antagonists were used. Plate-
let activation studies were done on 90 patients (41 with
unstable angina, 30 with non-Q-wave MI and 19 with
Q-wave MI) at enrollment (day 0) and on days 7 and 28. In
addition to the TIMI-12 subjects this report also includes
data obtained from two other groups of subjects. One
consisting of normal subjects and the other consisting of
patients studied in the Maine Medical Center emergency
department who were being admitted for various acute
medical problems not involving cardiovascular disease. The
mean age of the groups were: normal subjects, 36 6 10 (sd),
patient controls 66 6 13.3, TIMI-12 patients 57 6 11.
Fifty-five percent of the normal subjects, 40% of the patient
controls and 77% of the TIMI-12 patients were male. All
subjects were studied under protocols approved by the
appropriate institutional review boards for human research.
Blood samples were obtained through clean venipuncture
or free flowing intravenous lines after discarding the void
volume. All blood samples were collected in heparinized
tubes (Becton-Dickinson Vacutainer, Franklin Lakes, New
Jersey) and subsequent processing was done immediately at
the bedside using kits containing all of the required reagents
and supplied to the participating centers by our laboratory.
One drop (50 mL) of freshly drawn blood was placed
immediately into a tube containing 1 mL of 2% formalde-
hyde in phosphate buffered saline (PBS) solution and
mixed. Three aliquots of 0.5 mL each were placed into three
other tubes each containing zero, 1 mM or 5 mM (final
concentration) of adenosine diphosphate (ADP). After
mixing, the tubes were incubated for 5 minutes at room
temperature, and then 50 mL from each tube was trans-
ferred into three additional tubes containing 1 mL of 2%
formaldehyde. After 30 minutes at room temperature, the
fixed samples were diluted to 5 mL with PBS to dilute the
fixative. The result was four tubes of fixed whole blood, one
had been fixed immediately (spontaneous activation) and
the other three represented the result of activation after a 5
minute exposure to 0, 1 mM, and 5 mM ADP.
The fixed samples were refrigerated and shipped over-
night to our laboratory. The samples from the control
subjects were obtained and processed in exactly the same
way, using the same kits and the same reagents. On arrival,
the samples were washed with PBS to remove the fixative
and then labeled with saturating amounts of fluorescein
conjugated CD41 and biotinylated CD62P monoclonal
antibodies. After 20 minutes incubation at room tempera-
ture, the samples were washed once and incubated with
phycoerythrin conjugated streptavidin to label the bound
biotinylated antibody. After a further 20-minute incubation
the samples were washed again and analyzed using a Becton
Dickinson FACScan flow cytometer (Becton-Dickinson
Immunocytometry Systems, San Jose, California). The de-
tails of this analysis have been previously published (21,22).
Briefly the platelets were identified using the CD41 mono-
clonal which labeled all platelets, and the percentage of
P-Selectin positive platelets was determined by reference to
a negative control from which the CD62P monoclonal had
been omitted. Ten thousand platelets were analyzed in each
sample. In those samples that were stimulated with ADP,
there was often significant aggregation. The aggregates,
which also express elevated P-Selectin, were included in the
count of activated platelets. In the samples corresponding to
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spontaneous and zero ADP stimulation, there was no
significant aggregation and thus the measure of percent
activated platelets was not affected.
Statistical comparisons of baseline with day 7 and day 28
results within the TIMI-12 data were done using least
squares means of the change from baseline. Comparisons of
baseline platelet activation with the control groups were
done using unpaired Student’s t test. The significance of the
relationship between platelet activation and index event or
initial therapy was tested by two way repeated measures
ANOVA after checking that the interaction between base-
line characteristics and ADP dose was not significant.
RESULTS
Changes in platelet activation with time in the TIMI-12
subjects. Spontaneous platelet activation was significantly
elevated at baseline (27.6 6 18.7%) and decreased with time
over the 28 day treatment period to 16.7 6 13.4% at day 7
(p , 0.001) and 20.0 6 13.7% at day 28 (p 5 0.021).
Similar decreases were seen for the response to zero and
1 mM ADP but not for the response to 5 mM ADP (Fig. 1).
All measures of platelet activation at baseline on day 7 and
on day 28 showed no correlation with the dose of study drug
(data not shown). For this reason, the data for subjects
treated at all seven drug doses were combined for subse-
quent analysis.
Comparison of TIMI-12 results with control groups.
When compared to either control group, the levels of both
spontaneous platelet activation, and the response to no
ADP were significantly higher not only at baseline but also
at day 28 (Table 1). The responses to 1 mM and 5 mM ADP
were not significantly different from those of either control
group. The two control groups were not significantly dif-
ferent from each other.
Platelet activation and baseline covariates in the
TIMI-12 patients. Platelet activation response was signif-
icantly correlated with the type of index event (Fig. 2, upper
panel). Higher levels of platelet responses were seen in those
patients having Q-wave MI (19 patients), less in those with
non-Q-wave MI (30 patients) and least in those with
unstable angina (41 patients). Similarly, platelet activation
was significantly correlated with the type of treatment used
for the index event, prior to obtaining the baseline sample
(Fig. 2, lower panel). Patients treated with thrombolysis (18
Figure 1. Changes in platelet activation with time in TIMI-12 patients. Spontaneous platelet activation and the response to zero and
1 mM ADP were significantly higher at baseline than at day 7 or day 28. **p , 0.001; *p , 0.05 compared to baseline.
Table 1. Comparison of Platelet Activation in Control Groups and TIMI-12 Patients
Controls (Number) TIMI-12 (Number)
Normal
(10)
Patient
(10)
Baseline
(90)
Day 7
(75)
Day 28
(69)
Spontaneous 8.5 6 4.4 10.9 6 7.1 27.6 6 18.7** 16.7 6 13.4†† 20.0 6 13.7*†
0 mM ADP 14.8 6 8.7 13.3 6 6.8 36.1 6 17.1** 24.5 6 16.8*†† 25.9 6 14.8*†
1 mM ADP 50.7 6 18.4 57.2 6 16.2 48.2 6 19.1 44.1 6 20.3† 39.9 6 17†
5 mM ADP 68.2 6 13.6 67.8 6 13.3 64.8 6 19.1 67.9 6 17.7 66.4 6 13
Values shown are mean 6 sd. **p , 0.005 vs both normal and patient controls; *p , 0.05 vs. both normal and patient controls;
††p , 0.0001 vs. baseline; †p , 0.04 vs. baseline.
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patients) and primary percutaneous transluminal coronary
angioplasty (PTCA) (15 patients) had higher levels of activa-
tion than those with neither intervention (57 patients). When
analyzed separately, it was clear that most of the elevated
baseline platelet activation was in those patients who received
either thrombolysis or PTCA as primary therapy. Neverthe-
less, those receiving neither intervention also had a decrease in
platelet activation over time which was significant for the
0 mM ADP response but not for spontaneous activation (Table
2). There were no significant correlations between any measure
of platelet activation and age, weight, race or gender (data not
shown).
Figure 2. Correlation of platelet activation with index events and treatments. The relationship between platelet activation at baseline and
dose of ADP are shown for each index event in the upper panel, and for each primary therapy in the lower panel. Platelet activation
differed significantly by index event (p , 0.001) with highest activation seen in Q-wave MI patients and lowest activation seen in unstable
angina patients. Platelet activation was also higher in subjects receiving thrombolysis or primary PTCA as therapy, compared to subjects
receiving neither (p , 0.001). The number of patients in each group is shown in parentheses.
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Platelet activation and other laboratory parameters.
Weak correlations were observed between spontaneous
platelet activation and acute phase reactants c-reactive
protein and fibrinogen levels (r values of 0.2 and 0.3, p
values 0.02 and 0.04, respectively). In addition, there was a
weak correlation between all measures of platelet activation
and D-dimer levels (r values between 0.2 and 0.35, p values
between 0.004 and 0.05). No significant correlations were
observed with fibrinopeptide A or prothrombin activation
fragment 1 1 2.
DISCUSSION
Our results strongly suggest that patients presenting with
acute coronary syndromes have increased levels of platelet
activation that decrease with time after the event. The
design of this study does not allow us to clearly determine
whether the decreased platelet activation was due to the
drug treatment or to overall resolution of the coronary lesion
over time, although the lack of any correlation with drug
dose makes an effect of the drug less likely. The comparison
of the patients in TIMI-12 with two different control
groups also suggests that elevated platelet activation persists
for a considerable period in many patients following acute
coronary syndromes (ACS).
Although baseline platelet activation was higher for those
receiving treatment with either thrombolysis or PTCA,
there was also a decrease over time in those patients
receiving neither intervention. This suggests that increased
platelet activation may be due to both therapy and the
underlying disease process.
We have observed weak correlations between platelet
activation parameters and some acute phase reactants such
as C-reactive protein and fibrinogen which also decrease
over time following the acute event. Although these corre-
lations are not surprising, the weakness of the correlations
suggests that measurement of platelet activation is providing
a different type of information about the disease process
than these other measures of acute inflammation.
P-Selectin assay. One question that must be addressed is
whether the relatively high levels of platelet activation we
observed in the specimens that were fixed immediately
(spontaneous activation) are actually present in vivo. When
blood samples are obtained from normal subjects under
carefully controlled laboratory conditions, labeled and ana-
lyzed immediately, with or without fixation, considerably
lower levels of platelet activation are observed, in the range
of 1 to 5% (2,28). Thus, we feel that the levels of activation
reported here for normals are due to the fact that these
samples were obtained under “clinical conditions” and were
not analyzed immediately. The patient and control samples
were all obtained and the analyses performed under the
same conditions, thus permitting valid comparison between
the groups. Some of the activation observed even in the
immediately fixed samples may have occurred during or
after the drawing of the sample, prior to fixation. Further
studies will be necessary to make this distinction. Although
the normal subjects were significantly younger than the
patient control group, their platelet activation was not
different. This confirms our previous experience that platelet
activation does not change dramatically with age (unpub-
lished data).
The fact that these results could be obtained in a
multicenter study using “kits” sent out from a central
laboratory suggests that the measurement of platelet asso-
ciated P-Selectin is a relatively robust test that may find
clinical application in the future. It has been suggested that
measurement of soluble P-Selectin (29–31) may also reflect
increased platelet activation in similar settings. Since soluble
P-Selectin could in theory arise either from platelets or from
endothelial cells, the question of whether platelet associated
P-Selectin and soluble P-Selectin are providing the same or
different information about the disease process remains to
be answered.
Chronic oral GPIIb/IIIa inhibition. With the advent of
both parenteral and oral agents that strongly inhibit platelet
function, physicians now have tools that permit direct
manipulation of platelet function during and after a coro-
nary event. The questions that remain to be answered are
which patients should receive these new agents and for how
long they should be administered in order to prevent
platelets from triggering or participating in subsequent
thrombosis. Our results suggest that measurement of plate-
let activation may be one way to determine which patients
have a major component of platelet involvement in their
Table 2. Changes in Platelet Activation with Time in Treatment Groups
Baseline Day 7 Day 28
Spontaneous
Thrombolysis 33.9 6 20.9 16.1 6 11.0 (0.001) 23.7 6 15.1 (ns)
PTCA 36.3 6 21.2 15.5 6 10.9 (0.001) 20.9 6 12.7 (0.02)
Neither 23.2 6 16.2 17.4 6 15.2 (ns) 18.5 6 13.6 (ns)
0 mM ADP
Thrombolysis 43.9 6 16.3 22.9 6 10.6 (0.001) 27.4 6 15.7 (0.002)
PTCA 40.8 6 21.0 25.0 6 21.5 (0.004) 28.8 6 16.3 (0.05)
Neither 32.3 6 14.6 25.0 6 17.1 (0.04) 24.3 6 14.1 (0.02)
Values shown are mean 6 sd with the p value for the change from baseline in parentheses.
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disease process and thus may benefit most from platelet
inhibition. They also suggest that prolonged inhibition of
platelet function may be needed to allow platelets to return
to baseline low levels of responsiveness, thereby reducing the
risk of recurrent ischemic events. This hypothesis for the
potential clinical benefit of long-term oral GPIIb/IIIa
inhibition is currently being tested in large clinical trials.
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